Factor VII

	WikiDoc Resources for Factor VII
Articles
Most recent articles on Factor VII Most cited articles on Factor VII Review articles on Factor VII Articles on Factor VII in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Factor VII Images of Factor VII Photos of Factor VII Podcasts & MP3s on Factor VII Videos on Factor VII
Evidence Based Medicine
Cochrane Collaboration on Factor VII Bandolier on Factor VII TRIP on Factor VII
Clinical Trials
Ongoing Trials on Factor VII at Clinical Trials.gov Trial results on Factor VII Clinical Trials on Factor VII at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Factor VII NICE Guidance on Factor VII NHS PRODIGY Guidance FDA on Factor VII CDC on Factor VII
Books
Books on Factor VII
News
Factor VII in the news Be alerted to news on Factor VII News trends on Factor VII
Commentary
Blogs on Factor VII
Definitions
Definitions of Factor VII
Patient Resources / Community
Patient resources on Factor VII Discussion groups on Factor VII Patient Handouts on Factor VII Directions to Hospitals Treating Factor VII Risk calculators and risk factors for Factor VII
Healthcare Provider Resources
Symptoms of Factor VII Causes & Risk Factors for Factor VII Diagnostic studies for Factor VII Treatment of Factor VII
Continuing Medical Education (CME)
CME Programs on Factor VII
International
Factor VII en Espanol Factor VII en Francais
Business
Factor VII in the Marketplace Patents on Factor VII
Experimental / Informatics
List of terms related to Factor VII

Coagulation factor VII (serum prothrombin conversion accelerator)
	Anchoring of coagulation factor VIIa to the mebrane through its Gla domain
Identifiers
Symbols	F7 ;
External IDs	Template:OMIM5 Template:MGI HomoloGene: 7710
Gene ontology
Molecular function	Template:GNF GO Template:GNF GO Template:GNF GO
Cellular component	Template:GNF GO
Biological process	Template:GNF GO Template:GNF GO
RNA expression pattern
	More reference expression data
Orthologs
	Template:GNF Ortholog box

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Factor VII (formerly known as proconvertin) is one of the central proteins in the coagulation cascade. It is an enzyme (EC 3.4.21.21) of the serine protease class.

Physiology

The main role of factor VII (FVII) is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels - normally not exposed to the bloodstream. Upon vessel injury, tissue factor is exposed to the blood and circulating factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), activated factor X and the FVIIa-TF complex itself. The most important substrates for FVIIa-TF are Factor X and Factor IX.

The action of the factor is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent; it is produced in the liver. Use of warfarin or similar anticoagulants impairs its function.

Genetics

The gene for factor VII is located on chromosome 13 (13q34).

Role in disease

Deficiency is rare (congenital proconvertin deficiency) and inherits recessively.

Therapeutic use

Recombinant human factor VIIa (NovoSeven®, eptacog alfa [activated], ATC code B02BD08) has been introduced for use in uncontrollable bleeding in hemophilia patients (with Factor VIII or IX deficiency) who have developed inhibitors against replacement coagulation factor.

It is being increasingly used in uncontrollable hemorrhage.^[1] The first report of its use was in an Israeli soldier with uncontrollable bleeding in 1999.^[2] The rationale for its use in hemorrhage is, that it will only induce coagulation in those sites where tissue factor (TF) is also present. Still, O'Connell et al report an increased risk of deep vein thrombosis, pulmonary embolism and myocardial infarction in association with the use of rhFVIIa.^[3]

According to a 2005 study, recombinant human factor VII improves outcomes in acute intracerebral hemorrhage.^[4]

References

↑ Roberts H, Monroe D, White G (2004). "The use of recombinant factor VIIa in the treatment of bleeding disorders". Blood. 104 (13): 3858–64. PMID 15328151.
↑ Kenet G, Walden R, Eldad A, Martinowitz U (1999). "Treatment of traumatic bleeding with recombinant factor VIIa". Lancet. 354 (9193): 1879. PMID 10584732.
↑ O'Connell K, Wood J, Wise R, Lozier J, Braun M (2006). "Thromboembolic adverse events after use of recombinant human coagulation factor VIIa". JAMA. 295 (3): 293–8. PMID 16418464.
↑ Mayer S, Brun N, Begtrup K, Broderick J, Davis S, Diringer M, Skolnick B, Steiner T (2005). "Recombinant activated factor VII for acute intracerebral hemorrhage". N. Engl. J. Med. 352 (8): 777–85. PMID 15728810.

External links

Web site for novoseven-us.com